Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

(Oldenburg, IN) – Oldenburg Academy teacher Helen Yane has been awarded the Lilly Teacher Creativity Fellowship. According to the Lilly Endowment, this competitive program “enables educators to pursue ...

(Oldenburg, Ind.) - Oldenburg Academy teacher Helen Yane has been awarded the Lilly Teacher Creativity Fellowship. According to the Lilly Endowment, this competitive program “enables educators to ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

Quinn will still be with us here on CBS News York, but the News at 5 p.m. is going to look a little different without Dubois, ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly pre-announced a sizable Q4 2024 revenue miss headed into the big J.P. Morgan healthcare investor conference, but the biopharma reported massive growth. A lot of the quarterly ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...

Eli Lilly and Company (NYSE:LLY) shares slid 6.6% to $744.91, after it said it expects Q4 revenue at $13.5 billion- weaker than street expectations of $14.08 billion. The miss was driven largely ...

In Eli Lilly's most recent quarter, which ended on Sept. 30, 2024, it grew its sales by 20% to $11.4 billion. It also had multiple products that generated over $1 billion in revenue, including its ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...